FDA declines to approve Bristol-Myers hepatitis drug

November 26, 2014 6:06 PM

7 0

(Reuters) - Bristol-Myers Squibb Co on Wednesday said U.S. regulators had declined to approve the use of its experimental treatment for hepatitis C, daclatasvir, in combination with other antiviral drugs.

Bristol-Myers said it had initially sought permission from the U.S. Food and Drug Administration to market the drug, a so-called NS5A inhibitor, in combination with asunaprevir, one of the New York-based company's experimental medicines.

Also read: U.S. motor travel up 1.5 percent in April from year ago: DOT

Read more

To category page

Loading...